×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:ENDP

Endo International Stock Forecast, Price & News

$0.37
-0.02 (-5.72%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.36
$0.40
50-Day Range
$0.30
$2.74
52-Week Range
$0.28
$7.07
Volume
22.15 million shs
Average Volume
10.00 million shs
Market Capitalization
$86.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
30 days | 90 days | 365 days | Advanced Chart

Receive ENDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endo International and its competitors with MarketBeat's FREE daily newsletter.

ENDP Stock Forecast (MarketRank)

Overall MarketRank

1.81 out of 5 stars

Medical Sector

774th out of 1,411 stocks

Pharmaceutical Preparations Industry

378th out of 672 stocks

Analyst Opinion: 2.9Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
Endo International logo

About Endo International (NASDAQ:ENDP)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

ENDP Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ENDP
CUSIP
29264F20
Employees
3,103
Year Founded
1997

Company Calendar

Last Earnings
5/05/2022
Today
6/26/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+715.9%
Consensus Rating
Hold
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Net Income
$-613.24 million
Pretax Margin
-22.60%

Debt

Sales & Book Value

Annual Sales
$2.99 billion
Cash Flow
$5.25 per share
Book Value
($5.32) per share

Miscellaneous

Free Float
228,766,000
Market Cap
$86.45 million
Optionable
Optionable
Beta
1.12

Social Links















Endo International Frequently Asked Questions

Should I buy or sell Endo International stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Endo International stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENDP, but not buy additional shares or sell existing shares.
View analyst ratings for Endo International
or view top-rated stocks.

What is Endo International's stock price forecast for 2022?

4 brokers have issued 1-year price targets for Endo International's stock. Their ENDP stock forecasts range from $1.00 to $6.00. On average, they expect Endo International's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 715.9% from the stock's current price.
View analysts' price targets for Endo International
or view top-rated stocks among Wall Street analysts.

How has Endo International's stock price performed in 2022?

Endo International's stock was trading at $3.76 at the beginning of the year. Since then, ENDP stock has decreased by 90.2% and is now trading at $0.3677.
View the best growth stocks for 2022 here
.

Are investors shorting Endo International?

Endo International saw a decrease in short interest in May. As of May 31st, there was short interest totaling 25,040,000 shares, a decrease of 22.1% from the May 15th total of 32,140,000 shares. Based on an average trading volume of 9,940,000 shares, the short-interest ratio is currently 2.5 days.
View Endo International's Short Interest
.

When is Endo International's next earnings date?

Endo International is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Endo International
.

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) issued its quarterly earnings data on Thursday, May, 5th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.22. The business earned $652.26 million during the quarter, compared to the consensus estimate of $637.09 million. Endo International had a negative net margin of 24.82% and a negative trailing twelve-month return on equity of 72.22%. The company's revenue for the quarter was down 9.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.73 EPS.
View Endo International's earnings history
.

What guidance has Endo International issued on next quarter's earnings?

Endo International updated its second quarter 2022 earnings guidance on Monday, May, 23rd. The company provided EPS guidance of -$0.17--$0.15 for the period, compared to the consensus EPS estimate of $0.48. The company issued revenue guidance of $500.00 million-$525.00 million, compared to the consensus revenue estimate of $655.56 million.

Who are Endo International's key executives?

Endo International's management team includes the following people:
  • Mr. Blaise A. Coleman, Pres, CEO & Director (Age 48, Pay $20.93M)
  • Mr. Mark T. Bradley, Exec. VP & CFO (Age 52, Pay $6.27M)
  • Mr. Matthew Joseph Maletta, Exec. VP, Chief Legal Officer & Company Sec. (Age 50, Pay $7.02M)
  • Mr. Patrick A. Barry, Exec. VP & Pres of Global Commercial Operations (Age 54, Pay $6.15M)
  • Frank B. Raciti, VP, Controller & Chief Accounting Officer
  • Ms. Cheryl Stouch, Sr. VP of Information Technology & Chief Information Officer
  • Ms. Laure E. Park, Sr. VP of Investor Relations & Corp. Affairs
  • Ms. Susan Williamson, Sr. VP & Chief Compliance Officer
  • Ms. Tracy Basso, Chief HR Officer
  • Mr. James Papp, Head of Endo Ventures Limited & Sr. VP of Global Supply Chain

What is Paul Campanelli's approval rating as Endo International's CEO?

25 employees have rated Endo International CEO Paul Campanelli on Glassdoor.com. Paul Campanelli has an approval rating of 86% among Endo International's employees.

What other stocks do shareholders of Endo International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

Who are Endo International's major shareholders?

Endo International's stock is owned by a variety of institutional and retail investors. Top institutional investors include LSV Asset Management (0.90%), Bank of New York Mellon Corp (0.88%), Rhumbline Advisers (0.22%), Mitsubishi UFJ Trust & Banking Corp (0.19%), New York State Common Retirement Fund (0.18%) and California State Teachers Retirement System (0.13%). Company insiders that own Endo International stock include International Plc Endo, Roger H Kimmel and Shane Cooke.
View institutional ownership trends for Endo International
.

Which institutional investors are selling Endo International stock?

ENDP stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Simplex Trading LLC, Walleye Trading LLC, Jane Street Group LLC, Bank of New York Mellon Corp, Russell Investments Group Ltd., Group One Trading L.P., and California State Teachers Retirement System.
View insider buying and selling activity for Endo International
or view top insider-selling stocks.

Which institutional investors are buying Endo International stock?

ENDP stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, UBS Group AG, Mitsubishi UFJ Trust & Banking Corp, State of Tennessee Treasury Department, First Quadrant LLC CA, NorthCrest Asset Manangement LLC, Sterling Investment Advisors Ltd., and Carolina Wealth Advisors LLC.
View insider buying and selling activity for Endo International
or or view top insider-buying stocks.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $0.37.

How much money does Endo International make?

Endo International (NASDAQ:ENDP) has a market capitalization of $86.45 million and generates $2.99 billion in revenue each year. The company earns $-613.24 million in net income (profit) each year or ($3.12) on an earnings per share basis.

How many employees does Endo International have?

Endo International employs 3,103 workers across the globe.

When was Endo International founded?

Endo International was founded in 1997.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The official website for Endo International is www.endo.com. The company can be reached via phone at (531) 268-2000, via email at [email protected], or via fax at 800-329-3636.

This page (NASDAQ:ENDP) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.